EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cognitive Impairment in Multiple Sclerosis

Kenneth Maiese iD

Bioengineering · 23.07.2023 · 10 (7) · 871

DOI: 10.3390/bioengineering10070871 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bioengineering, online erschienen am 23.07.2023. Verfasst von Kenneth Maiese. Beteiligte Einrichtung: Cellular and Molecular Signaling, New York, NY 10022, USA. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 477 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, American Diabetes Association, American Heart Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Almost three million individuals suffer from multiple sclerosis (MS) throughout the world, a demyelinating disease in the nervous system with increased prevalence over the last five decades, and is now being recognized as one significant etiology of cognitive loss and dementia. Presently, disease modifying therapies can limit the rate of relapse and potentially reduce brain volume loss in patients with MS, but unfortunately cannot prevent disease progression or the onset of cognitive disability. Innovative strategies are therefore required to address areas of inflammation, immune cell activation, and cell survival that involve novel pathways of programmed cell death, mammalian forkhead transcription factors (FoxOs), the mechanistic target of rapamycin (mTOR), AMP activated protein kinase (AMPK), the silent mating type information regulation 2 homolog 1 (Saccharomyces cerevisiae) (SIRT1), and associated pathways with the apolipoprotein E (APOE-ε4) gene and severe acute respiratory syndrome coronavirus (SARS-CoV-2). These pathways are intertwined at multiple levels and can involve metabolic oversight with cellular metabolism dependent upon nicotinamide adenine dinucleotide (NAD+). Insight into the mechanisms of these pathways can provide new avenues of discovery for the therapeutic treatment of dementia and loss in cognition that occurs during MS.

Schlagwörter

Stichwörter der Autor:innen

APOE-ε4COVID-19FoxOSIRT1apoptosisautophagydementiamTORmultiple sclerosisnicotinamide

Autor:innen und Institutionen

  • Cellular and Molecular Signaling, New York, NY 10022, USA.

ORCID-Profile: Kenneth Maiese

Förderung

  • NIH HHS
  • American Diabetes Association
  • American Heart Association
  • NIH NIEHS
  • NIH NIA
  • NIH NINDS
  • NS053956
  • NIH ARRA

Zitieren

APA

Maiese, K. (2023). Cognitive Impairment in Multiple Sclerosis. Bioengineering, 10(7), 871. https://doi.org/10.3390/bioengineering10070871

Vancouver

Maiese K. Cognitive Impairment in Multiple Sclerosis. Bioengineering. 2023;10(7):871. doi:10.3390/bioengineering10070871

BibTeX
@article{Maiese2023,
  author = {Maiese, Kenneth},
  title = {Cognitive Impairment in Multiple Sclerosis},
  journal = {Bioengineering},
  year = {2023},
  volume = {10},
  number = {7},
  pages = {871},
  doi = {10.3390/bioengineering10070871}
}
Kostenlos starten →